| This week's sponsor is FierceBiotech’s Drug Development Forum. | | FierceBiotech’s Drug Development Forum – September 19-21, 2016 Join leading biotech professionals in the first-ever Drug Development Forum in Boston. Discover the latest trends, challenges, and innovations in the biotech industry. Sign up by July 29, 2016 and save $200 on registration.
Register now |
Top Stories Wednesday, July 13, 2016 Amgen took one step closer to approval for its biosimilar of the world’s biggest-selling drug last night, but analysts don’t see it hitting the market this side of 2020 as a bitter patent battle continues. Wednesday, July 13, 2016 Analysts at Jefferies have found that Biogen has quietly sneaked a lupus candidate into the lab for initial testing, coming as it does after the Big Biotech has in recent months cut its lupus research programs. Wednesday, July 13, 2016 Already having an existing collab in diabetes, Eli Lilly and Germany’s Boehringer Ingelheim have today announced a new research pact, this time focused on breast cancer. Wednesday, July 13, 2016 Roivant Sciences and Plexcera Therapeutics have today launched a new biotech company with a singular focus on the ultrarare condition known as Farber disease, as Roivant continues with its spinoff strategy. Tuesday, July 12, 2016 MyoKardia is working on making good on its IPO last fall. It’s up by more than one-third on early data for its lead candidate in hypertrophic cardiomyopathy. MyoKardia plans to head into Phase II testing for the candidate, MYK-461, during this half of 2016. Wednesday, July 13, 2016 Motif Bio is forging ahead with plans to list its stock on Nasdaq. The British biotech has formalized its long-standing interest in a U.S. listing by filing paperwork with the SEC, setting it up for an IPO it hopes will deliver the cash it needs to wrap up a Phase III trial of its antibiotic, iclaprim. | | | California’s Second Genome has named Glenn Nedwin as its new CEO while also saying it has expanded its Series B financing round to $51 million. Release Illinois biotech Aptinyx has started dosing in a Phase I study of its lead NMDA-receptor modulator NYX-2925. Statement San Diego biotech Oncternal Therapeutics' TK216 has been given Orphan Drug Designation for the treatment of Ewing sarcoma. Release Loxo Oncology has received a breakthrough designation from the FDA for its cancer candidate LOXO-101. Statement | |
|
Resources Sponsored by: SDC Interested in intended use validation of SaaS-based EDC systems? Prefer to discuss rescue study strategies and considerations? How about understanding statistical power for non-statisticians? Vote for your favorite webinar topic to be presented by SDC at DIA on June 28, 2016, 12pm EDT. Cast Your Vote Here to receive your exclusive event invitation and a recording of the webinar after the event. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. FierceBiotech Drug Development Forum September 19-21, 2016 | Boston, MA Immunotherapy: Mapping the future July 28, 2016 | Foster City, CA BioImmersion: In Depth Biotech for the Non-Scientist October 5-7, 2016 | Chicago, IL Drug Development Boot CampTM 2016 November 16-17, 2016 | Boston, MA Characterization of Animal Models for Alzheimer’s disease: Webinar Presented by Charles River July 19, 2016 Master of Science in Bioinformatics at Northeastern University Fall 2016, Spring 2017 Courses BIOSPAIN 2016 September 28-30, 2016 | Bilbao, Basque Country, Spain |
